Compare AMR & LKFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMR | LKFT |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2017 | 2007 |
| Metric | AMR | LKFT |
|---|---|---|
| Price | $171.20 | $29.96 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 6 |
| Target Price | ★ $178.33 | $30.21 |
| AVG Volume (30 Days) | 239.2K | ★ 311.4K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,129,481,000.00 | N/A |
| Revenue This Year | $2.08 | N/A |
| Revenue Next Year | $19.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $133.64 | $25.68 |
| 52 Week High | $253.82 | $32.41 |
| Indicator | AMR | LKFT |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 55.86 |
| Support Level | $170.29 | $26.63 |
| Resistance Level | $199.32 | $30.08 |
| Average True Range (ATR) | 7.51 | 0.75 |
| MACD | 0.29 | -0.01 |
| Stochastic Oscillator | 29.22 | 78.26 |
Alpha Metallurgical Resources Inc is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company's portfolio of mining operations consists of underground mines, surface mines, and coal preparation plants. It produces low-ash metallurgical coal, including High-Vol. A, Mid-Vol., High-Vol. B, and Low-Vol. coal, which is shipped to domestic and international coke and steel producers. The reportable segment of the company is Met. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.